Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3384 Target Snapshot

Serine/threonine-protein kinase N1 · SINGLE PROTEIN · Homo sapiens

714Compounds
263Assays
11Approved Drugs
524.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q16512. Use UniProt Q16512 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q16512 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase N1 as ChEMBL target CHEMBL3384, mapped to UniProt Q16512. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase N1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3384
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16512
Serine/threonine-protein kinase N1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase N1 is the right protein anchor across sources, using UniProt Q16512 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase N1
UniProt AccessionQ16512
Component TypeProtein
Sequence Length942 aa

Serine/threonine-protein kinase N1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase N1, mapped to UniProt Q16512. Sequence length is 942 aa.

Mapped IDQ16512
Review nameSerine/threonine-protein kinase N1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

11
Approved
11
Phase III
12
Phase II
16
Phase I
Assay Mix

Activity Type Distribution

IC50118.0
KI37.0
KD369.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.7 IC50 0.199 Preclinical
CHEMBL3597011 9.0 IC50 1.0 Preclinical
CHEMBL5687042 9.0 IC50 1.0 Preclinical
CHEMBL388978 8.89 Kd 1.3 Preclinical
CHEMBL5687026 8.8 IC50 1.6 Preclinical
CHEMBL5687057 8.4 IC50 4.0 Preclinical
CHEMBL5687053 8.3 IC50 5.0 Preclinical
CHEMBL603469 8.28 Kd 5.3 Clinical
CHEMBL4576489 8.22 Kd 6.0 Preclinical
CHEMBL1214929 8.15 IC50 7.0 Preclinical
Distribution

pChEMBL Value Distribution

18
5.0
29
5.5
26
6.0
26
6.5
11
7.0
9
7.5
17
8.0
4
8.5
4
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
TOFACITINIB
CHEMBL221959
Approved 2012
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

263
Total Assays
131
Tested Compounds
1
Assay Types
Binding — 263 assays, 131 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 210 87 6.3
assay format 25 5 5.3
subcellular format 17 37 6.2
cell-based format 11 2 8.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine